Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study on the Safety and Efficacy of CAR19-BCMA Dual-target CAR-T Cell Therapy for Relapsed/Refractory Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

NCT06986434 is registered in ClinicalTrials.gov with Affiliated Hospital to Academy of Military Medical Sciences as lead sponsor.

NCT NCT06986434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06986434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study on the Safety and Efficacy of CAR19-BCMA Dual-target CAR-T Cell Therapy for Relapsed/Refractory Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Lead sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 2, 2026
Completion date
August 25, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphomas/leukemias with plasmacytic differentiation, relapsed or refractory plasma cell neoplasms